MX2022001505A - Composiciones de trofinetida. - Google Patents

Composiciones de trofinetida.

Info

Publication number
MX2022001505A
MX2022001505A MX2022001505A MX2022001505A MX2022001505A MX 2022001505 A MX2022001505 A MX 2022001505A MX 2022001505 A MX2022001505 A MX 2022001505A MX 2022001505 A MX2022001505 A MX 2022001505A MX 2022001505 A MX2022001505 A MX 2022001505A
Authority
MX
Mexico
Prior art keywords
compositions
compounds
trofinetide
products
methods
Prior art date
Application number
MX2022001505A
Other languages
English (en)
Inventor
Clive Blower
Mathew Peterson
James Murray Shaw
James Anthony Bonnar
Etienne David Frank Philippe Moniotte
Martin Bernard Catherine Bousmanne
Cecilia Betti
Karel Willy Luc Decroos
Mimoun Ayoub
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of MX2022001505A publication Critical patent/MX2022001505A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18—Carbon
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta descripción describe compuestos de Fórmula (I), estereoisómeros, compuestos secundarios de estos, composiciones farmacéuticas y métodos para elaborar tales compuestos, que utilizan reactivos de sililación y que producen composiciones y productos preparados utilizando tales métodos. Más particularmente, esta divulgación describe la elaboración de trofinetida y productos secundarios, composiciones y productos que contienen tales compuestos, para usos farmacéuticos con el fin de tratar trastornos neurodegenerativos o del neurodesarrollo.
MX2022001505A 2019-08-05 2020-08-03 Composiciones de trofinetida. MX2022001505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882998P 2019-08-05 2019-08-05
PCT/US2020/044733 WO2021026066A1 (en) 2019-08-05 2020-08-03 Compositions of trofinetide

Publications (1)

Publication Number Publication Date
MX2022001505A true MX2022001505A (es) 2022-03-11

Family

ID=74502416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001505A MX2022001505A (es) 2019-08-05 2020-08-03 Composiciones de trofinetida.

Country Status (14)

Country Link
US (3) US11370755B2 (es)
EP (1) EP4009962A4 (es)
JP (1) JP2022543391A (es)
KR (1) KR20220059479A (es)
CN (1) CN114667136A (es)
AU (1) AU2020324396A1 (es)
BR (1) BR112022002229A2 (es)
CA (1) CA3149633A1 (es)
CL (1) CL2022000301A1 (es)
CO (1) CO2022002616A2 (es)
IL (1) IL290324A (es)
JO (1) JOP20220027A1 (es)
MX (1) MX2022001505A (es)
WO (1) WO2021026066A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020324396A1 (en) 2019-08-05 2022-03-10 Neuren Pharmaceuticals Limited Compositions of trofinetide
WO2023287750A1 (en) * 2021-07-12 2023-01-19 Acadia Pharmaceuticals Inc. Crystalline forms of trofinetide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573765B1 (fr) * 1984-11-23 1988-06-10 Solvay Procede pour la synthese de peptides
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
AU2002303856A1 (en) 2001-05-24 2002-12-03 Neuronz Limited Gpe analogs and peptidomimetics
EP1888618A4 (en) * 2005-05-23 2009-07-15 Neuren Pharmaceuticals Ltd GLYCYL-PROLYL-GLUTAMATE ANALOGS
JP5220724B2 (ja) * 2006-03-14 2013-06-26 ニューレン ファーマシューティカルズ リミテッド グリシル−２−メチルプロリルグルタミン酸塩の経口製剤
EP2060580A1 (en) * 2007-11-19 2009-05-20 SOLVAY (Société Anonyme) Process for the manufacture of persilylated peptides
US9708366B2 (en) 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
AU2020324396A1 (en) * 2019-08-05 2022-03-10 Neuren Pharmaceuticals Limited Compositions of trofinetide

Also Published As

Publication number Publication date
BR112022002229A2 (pt) 2022-04-19
US11866406B2 (en) 2024-01-09
EP4009962A1 (en) 2022-06-15
US20220324799A1 (en) 2022-10-13
IL290324A (en) 2022-04-01
CL2022000301A1 (es) 2022-09-20
JP2022543391A (ja) 2022-10-12
US20220055987A1 (en) 2022-02-24
CN114667136A (zh) 2022-06-24
US20240109841A1 (en) 2024-04-04
AU2020324396A1 (en) 2022-03-10
US11370755B2 (en) 2022-06-28
EP4009962A4 (en) 2023-08-09
CA3149633A1 (en) 2021-02-11
KR20220059479A (ko) 2022-05-10
JOP20220027A1 (ar) 2023-01-30
WO2021026066A1 (en) 2021-02-11
CO2022002616A2 (es) 2022-06-10

Similar Documents

Publication Publication Date Title
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
TN2015000018A1 (en) 5-ht3 receptor antagonists
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
MX2017005281A (es) Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2022001505A (es) Composiciones de trofinetida.
PH12019500198A1 (en) Compounds and compositions and uses thereof
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
MX2016010529A (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
NZ740119A (en) Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
MX2019000276A (es) Nuevos derivados ciclopropílicos.